Immune system

DGAP-News: CureVac : CureVac Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate, CVnCoV

Friday, October 23, 2020 - 1:07pm

CureVac : CureVac Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate, CVnCoV

Key Points: 
  • CureVac : CureVac Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate, CVnCoV
    The issuer is solely responsible for the content of this announcement.
  • The vaccine candidate elicited balanced humoral and cellular immune responses, featuring high antibody titers and very good T cell activation.
  • In addition to the positive immune response, the vaccine candidate induced favorable Th1 cytokine levels.
  • The full manuscript of the preclinical data is available on the pre-print server bioRxiv and was submitted for potential publication in a peer-reviewed journal.

ONCURIOUS I-O Portfolio Directed at Boosting T Cell Influx and Activity in Solid Tumors; Announcing First Preclinical Proof of Concept in Proprietary CCR8 Treg Program

Thursday, October 22, 2020 - 10:04pm

- Preclinical Proof of Concept for Company's priority I-O program, aiming at depleting regulatory T cells (Tregs) by targeting C-C motif chemokine receptor 8 (CCR8)

Key Points: 
  • - Preclinical Proof of Concept for Company's priority I-O program, aiming at depleting regulatory T cells (Tregs) by targeting C-C motif chemokine receptor 8 (CCR8)
    - Initiating lead optimization phase in proprietaryCCR8 Treg Program.
  • This important milestone follows Oncurious' decision to focus its development activities on a pipeline of promising novel immune-oncology targets and drug discovery projects.
  • Oncurious is now accelerating its efforts towards initiation of preclinical development of the therapeutic antibody program in early 2021.
  • Next to the anti-CCR8 program, Oncurious is focusing on 2 other programs aimed at boosting anti-tumor T cell influx and activity in immune excluded tumors.

ONCURIOUS I-O Portfolio Directed at Boosting T Cell Influx and Activity in Solid Tumors Announcing First Preclinical Proof of Concept in Proprietary CCR8 Treg Program

Thursday, October 22, 2020 - 5:47pm

Preclinical Proof of Concept for Companys priority I-O program, aiming at depleting regulatory T cells (Tregs) by targeting C-C motif chemokine receptor 8 (CCR8)

Key Points: 
  • Preclinical Proof of Concept for Companys priority I-O program, aiming at depleting regulatory T cells (Tregs) by targeting C-C motif chemokine receptor 8 (CCR8)
    Initiating lead optimization phase in proprietary CCR8 Treg Program.
  • This important milestone follows Oncurious decision to focus its development activities on a pipeline of promising novel immune-oncology targets and drug discovery projects.
  • Oncurious is now accelerating its efforts towards initiation of preclinical development of the therapeutic antibody program in early 2021.
  • Next to the anti-CCR8 program, Oncurious is focusing on 2 other programs aimed at boosting anti-tumor T cell influx and activity in immune excluded tumors.

OSE Immunotherapeutics Announces Publication Supporting Additional New Mechanism of Action for Selective Antibody Antagonist of SIRPα BI 765063 in the Journal of Clinical Investigation

Thursday, October 22, 2020 - 5:00pm

BI 765063 is currently being evaluated in a Phase 1 clinical trial conducted in patients with advanced solid tumors.

Key Points: 
  • BI 765063 is currently being evaluated in a Phase 1 clinical trial conducted in patients with advanced solid tumors.
  • OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases.
  • BI 765063 (OSE-172, anti-SIRP monoclonal antibody): developed in partnership with Boehringer Ingelheim; myeloid checkpoint inhibitor in Phase 1 in advanced solid tumors.
  • Positive preclinical and human ex vivo results in August 2020, clinical trial expected to start end of 2020/early 2021.

Vycellix CEO to Present its Universal Cell Program (VY-UC) for Off-the-Shelf NK Cell Therapy at Allogeneic Cell Therapies Summit

Thursday, October 22, 2020 - 4:30pm

Cells modified by VY-UC avoid immune recognition of grafted cells without impacting HLA while conserving viability, functionality, and persistence.

Key Points: 
  • Cells modified by VY-UC avoid immune recognition of grafted cells without impacting HLA while conserving viability, functionality, and persistence.
  • The Company has achieved proof-of-concept for VY-UC in a range of effector cell-based immunotherapies including T cells, CAR-T and NK cells.
  • He also serves as co-director of NextGenNK, an international Competence Center for the development of next-generation NK cell-based cancer immunotherapies based at KI.
  • Vycellix is a private, immuno-centric discovery life science company, advancing the development of transformational platform technologies to enhance and optimize next-generation cell & gene-based therapies, including T cell and natural killer (NK) cell-based cancer therapies.

Veritas Farms Signs Memorandum of Understanding With Pure Research Products, LLC to Access and Incorporate its Immune Technology in the Development of Additional Veritas Farms Products; Initiates Research Partnership

Thursday, October 22, 2020 - 2:08pm

Del-Immune V is one of the leading non-prescription cell fragment nutritional supplement supported by clinical research available in the United States.

Key Points: 
  • Del-Immune V is one of the leading non-prescription cell fragment nutritional supplement supported by clinical research available in the United States.
  • Alexander Salgado, CEO and Co-Founder, said, We are excited to begin this research and development partnership with Pure Research Products.
  • In addition to Del-Immune V, Pure Research Products, offers a full line of human and pet immune support supplements.
  • Pure Research Products, which serves customers globally, is based in Boulder, Colo., and the Del-Immune V products are manufactured in Greenfield, Ind.

F-star Therapeutics to Present at SITC 2020 Virtual Annual Meeting

Thursday, October 22, 2020 - 1:00pm

CAMBRIDGE,England and CAMBRIDGE, Mass., Oct. 22, 2020 /PRNewswire/ --F-star Therapeutics Ltd., a clinical-stage immuno-oncology company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb2) antibodies, today announced that it will present two posters at the Society for Immunotherapy of Cancer's (SITC) 35th Virtual Annual Meeting being held from Monday, November 9, 2020 to Saturday, November 14, 2020.

Key Points: 
  • CAMBRIDGE,England and CAMBRIDGE, Mass., Oct. 22, 2020 /PRNewswire/ --F-star Therapeutics Ltd., a clinical-stage immuno-oncology company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb2) antibodies, today announced that it will present two posters at the Society for Immunotherapy of Cancer's (SITC) 35th Virtual Annual Meeting being held from Monday, November 9, 2020 to Saturday, November 14, 2020.
  • The posters will focus on FS118, F-star's potentially first-in-class, tetravalent bispecific antibody that simultaneously blocks both the LAG-3 and PD-L1 immunosuppressive pathways.
  • Abstracts are available on the SITC website and the accompanying posters will be available in the Virtual Poster Hall open from 8:00 am EST on Monday, November 9, until the Virtual Poster Hall closes on December 31, 2020.
  • Through its proprietary tetravalent, bispecific antibody (mAb) format, F-star's mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability.

F-star Therapeutics to Present at SITC 2020 Virtual Annual Meeting

Thursday, October 22, 2020 - 1:00pm

CAMBRIDGE,England and CAMBRIDGE, Massachusetts, Oct. 22, 2020 /PRNewswire/ --F-star Therapeutics Ltd., a clinical-stage immuno-oncology company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb2) antibodies, today announced that it will present two posters at the Society for Immunotherapy of Cancer's (SITC) 35th Virtual Annual Meeting being held from Monday, November 9, 2020 to Saturday, November 14, 2020.

Key Points: 
  • CAMBRIDGE,England and CAMBRIDGE, Massachusetts, Oct. 22, 2020 /PRNewswire/ --F-star Therapeutics Ltd., a clinical-stage immuno-oncology company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb2) antibodies, today announced that it will present two posters at the Society for Immunotherapy of Cancer's (SITC) 35th Virtual Annual Meeting being held from Monday, November 9, 2020 to Saturday, November 14, 2020.
  • The posters will focus on FS118, F-star's potentially first-in-class, tetravalent bispecific antibody that simultaneously blocks both the LAG-3 and PD-L1 immunosuppressive pathways.
  • Abstracts are available on the SITC website and the accompanying posters will be available in the Virtual Poster Hall open from 8:00 am EST on Monday, November 9, until the Virtual Poster Hall closes on December 31, 2020.
  • Through its proprietary tetravalent, bispecific antibody (mAb) format, F-star's mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability.

Be Biopharma Launches with $52 Million Series A Financing to Advance B Cells as Medicines

Thursday, October 22, 2020 - 12:00pm

The company plans to use this funding to precisely engineer B cells to treat a range of diseases, building on the pioneering work of Drs.

Key Points: 
  • The company plans to use this funding to precisely engineer B cells to treat a range of diseases, building on the pioneering work of Drs.
  • B cells are prolific protein producers that can be collected from peripheral blood, have a programmable lifetime that could last decades, can target specific tissues, and have broad, customizable functionality.
  • Moreover, the varied functions of B cells suggest that B cell medicines can address a range of conditions including autoimmune diseases, cancer, and monogenic disorders, as well as enhance the immune response to infectious pathogens.
  • Be Biopharma is a leader in developing B cells as medicines, treating disease with the human bodys native protein factories.

Adicet Announces FDA Clearance of IND Application for First-in-Class Allogeneic CAR Gamma-Delta T Cell Therapy

Thursday, October 22, 2020 - 12:00pm

The clearance of the IND for ADI-001 by the FDA is a significant milestone in the development of CAR T cell therapies by Adicet, and marks the beginning of clinical development of a deep pipeline of off-the-shelf T cell products, said Chen Schor, President and Chief Executive Officer of Adicet.

Key Points: 
  • The clearance of the IND for ADI-001 by the FDA is a significant milestone in the development of CAR T cell therapies by Adicet, and marks the beginning of clinical development of a deep pipeline of off-the-shelf T cell products, said Chen Schor, President and Chief Executive Officer of Adicet.
  • We are particularly excited to advance on our goal to exploit the therapeutic potential of our first in class engineered CAR T cell therapy in NHL patients.
  • ADI-001 is an investigational allogeneic gamma delta T cell therapy being developed as a treatment for B-cell non-Hodgkins lymphoma (NHL).
  • Adicet is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases.